Skip to content
AnalystLens

Humana 8-K Report, Corporate Update (Nov 9, 2026)

Reports
Other Events·Exhibits & Filings
Filing Date
Filed November 9, 2026
Period End
November 9, 2026
Security
HUM
In the record · 2016–202610-K1110-Q338-K201

HUM filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 201 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · May ’17May ’17
  2. Material agreement8-K · Aug ’19Aug ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 8-K filed November 9, 2026. Cited figures are marked; the original filing is the authoritative source.

Humana Inc. (HUM) has announced the commencement of cash tender offers for certain of its outstanding debt securities, as detailed in an 8-K filing on November 9, 2026.

The company is seeking to purchase a portion of its existing debt, with an aggregate purchase price cap of $1,500,000,000,a excluding accrued interest. These offers are structured with specific acceptance priority levels for different series of notes, indicating a strategic approach to debt management. A notable condition includes a specific cap of $800,000,000 on the aggregate principal amount of the 5.375% Senior Notes due 2031 that will be accepted for purchase.

The tender offers are set to expire on November 16, 2026, with an expected settlement date of November 18, 2026. The total consideration for the notes will be determined based on a fixed spread plus the reference yield of specific U.S. Treasury securities on November 16, 2026, the Price Determination Date.

Investors holding these debt securities are advised to consult the Offer to Purchase for complete terms, conditions, and the specific process for tendering their notes. Humana has appointed several firms as dealer managers and a tender and information agent to facilitate these offers.

Key Highlights

  1. Humana Inc. launched cash tender offers for specific outstanding debt securities.
  2. The total aggregate purchase price is capped at $1,500,000,000, excluding accrued interest.
  3. A specific Series Cap of $800,000,000 is in place for the 5.375% Senior Notes due 2031.
  4. The tender offers prioritize different note series based on an assigned Acceptance Priority Level.
  5. The offers are scheduled to expire on November 16, 2026, with an expected settlement on November 18, 2026.
  6. The total consideration will be determined by a fixed spread plus the reference yield on November 16, 2026.
  7. The offers are subject to various conditions, including satisfaction or waiver by Humana.

Frequently Asked Questions

  1. What is the purpose of these tender offers?

    Humana is conducting these cash tender offers to purchase a portion of its outstanding debt securities. This is a common financial strategy for companies to manage their debt structure, potentially by refinancing at lower interest rates or optimizing their capital structure.

  2. What is the maximum amount Humana is willing to spend on these buybacks?

    Humana has set an aggregate purchase price cap of $1,500,000,000 for the debt securities being purchased, not including any accrued interest payments.

  3. Are all debt securities treated equally in this offer?

    No, the offers have different 'Acceptance Priority Levels' for each series of notes, meaning Humana will prioritize purchases based on these levels. Additionally, there's a specific cap of $800,000,000 for the 5.375% Senior Notes due 2031, which could limit the total amount accepted for that particular series, even if tendered in higher priority levels.

  4. When do investors need to act by?

    The tender offers are set to expire at 5:00 p.m. New York City time on November 16, 2026. Investors should be aware that their brokers or intermediaries may have earlier deadlines for submitting instructions.